205 related articles for article (PubMed ID: 29274134)
21. Monocytic Differentiation of Human Acute Myeloid Leukemia Cells: A Proteomic and Phosphoproteomic Comparison of FAB-M4/M5 Patients with and without Nucleophosmin 1 Mutations.
Selheim F; Aasebø E; Reikvam H; Bruserud Ø; Hernandez-Valladares M
Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791118
[TBL] [Abstract][Full Text] [Related]
22. Leukemogenic nucleophosmin mutation disrupts the transcription factor hub that regulates granulomonocytic fates.
Gu X; Ebrahem Q; Mahfouz RZ; Hasipek M; Enane F; Radivoyevitch T; Rapin N; Przychodzen B; Hu Z; Balusu R; Cotta CV; Wald D; Argueta C; Landesman Y; Martelli MP; Falini B; Carraway H; Porse BT; Maciejewski J; Jha BK; Saunthararajah Y
J Clin Invest; 2018 Oct; 128(10):4260-4279. PubMed ID: 30015632
[TBL] [Abstract][Full Text] [Related]
23. Morphologic, immunophenotypic, molecular genetic, and clinical characterization in patients with SRSF2-mutated acute myeloid leukemia.
Tatarian J; Tupper N; Li P; Feusier J; Abdo M; Hyter S; Gonzales PR; Zhang D; Woodroof J; Kelting S; Godwin AK; Cui W
Am J Clin Pathol; 2023 Nov; 160(5):490-499. PubMed ID: 37458189
[TBL] [Abstract][Full Text] [Related]
24. MRD evaluation of AML in clinical practice: are we there yet?
Freeman SD; Hourigan CS
Hematology Am Soc Hematol Educ Program; 2019 Dec; 2019(1):557-569. PubMed ID: 31808906
[TBL] [Abstract][Full Text] [Related]
25. Management of isocitrate dehydrogenase 1/2 mutated acute myeloid leukemia.
Fruchtman H; Avigan ZM; Waksal JA; Brennan N; Mascarenhas JO
Leukemia; 2024 May; 38(5):927-935. PubMed ID: 38600315
[TBL] [Abstract][Full Text] [Related]
26. RNA and protein expression of herpesvirus entry mediator (HVEM) is associated with molecular markers, immunity-related pathways and relapse-free survival of patients with AML.
Lichtenegger FS; Kondla I; Krempasky M; Weber AL; Herold T; Krupka C; Spiekermann K; Schneider S; Büchner T; Berdel WE; Wörmann BJ; Hiddemann W; Subklewe M
Cancer Immunol Immunother; 2015 Dec; 64(12):1505-15. PubMed ID: 26377688
[TBL] [Abstract][Full Text] [Related]
27. Myeloid neoplasm occurrence during stable molecular remission of NPM1-mutated AML: are we facing secondary disease or AML relapse?
Giupponi C; Bertoli D; Borlenghi E; Cattaneo C; Zollner T; Masina L; Bagnasco S; Cerqui E; Federico F; Pagani C; Archetti S; Brugnoni D; Rossi G; Tucci A
Blood Cancer J; 2023 Dec; 13(1):194. PubMed ID: 38129393
[No Abstract] [Full Text] [Related]
28. Isocitrate dehydrogenase 1 mutation drives leukemogenesis by PDGFRA activation due to insulator disruption in acute myeloid leukemia (AML).
Steinhäuser S; Silva P; Lenk L; Beder T; Hartmann A; Hänzelmann S; Fransecky L; Neumann M; Bastian L; Lipinski S; Richter K; Bultmann M; Hübner E; Xia S; Röllig C; Vogiatzi F; Schewe DM; Yumiceba V; Schultz K; Spielmann M; Baldus CD
Leukemia; 2023 Jan; 37(1):134-142. PubMed ID: 36411356
[TBL] [Abstract][Full Text] [Related]
29. Samples from patients with AML show high concordance in detection of mutations by NGS at local institutions vs central laboratories.
Borate U; Yang F; Press R; Ruppert AS; Jones D; Caruthers S; Zhao W; Vergilio JA; Pavlick DC; Juckett L; Norris B; Bucy T; Burd A; Stein EM; Patel P; Baer MR; Stock W; Schiller G; Blum W; Kovacsovics T; Litzow M; Foran J; Heerema NA; Rosenberg L; Marcus S; Yocum A; Stefanos M; Druker B; Byrd JC; Levine RL; Mims A
Blood Adv; 2023 Oct; 7(20):6048-6054. PubMed ID: 37459200
[TBL] [Abstract][Full Text] [Related]
30. Tumour-derived small extracellular vesicles suppress CD8+ T cell immune function by inhibiting SLC6A8-mediated creatine import in NPM1-mutated acute myeloid leukaemia.
Peng M; Ren J; Jing Y; Jiang X; Xiao Q; Huang J; Tao Y; Lei L; Wang X; Yang Z; Yang Z; Zhan Q; Lin C; Jin G; Zhang X; Zhang L
J Extracell Vesicles; 2021 Nov; 10(13):e12168. PubMed ID: 34807526
[TBL] [Abstract][Full Text] [Related]
31. Measurable Residual
Gui G; Dillon LW; Ravindra N; Hegde PS; Andrew G; Mukherjee D; Wong Z; Auletta J; El Chaer F; Chen E; Chen YB; Corner A; Devine SM; Iyer S; Jimenez Jimenez AM; De Lima MJG; Litzow MR; Kebriaei P; Spellman SR; Zeger SL; Page KM; Hourigan CS
medRxiv; 2023 Aug; ():. PubMed ID: 37577695
[TBL] [Abstract][Full Text] [Related]
32. TET2 mutations contribute to adverse prognosis in acute myeloid leukemia (AML): results from a comprehensive analysis of 502 AML cases and the Beat AML public database.
Pan X; Chang Y; Ruan G; Zhou S; Jiang H; Jiang Q; Huang X; Zhao XS
Clin Exp Med; 2024 Feb; 24(1):35. PubMed ID: 38349460
[TBL] [Abstract][Full Text] [Related]
33. Human erythroleukemia genetics and transcriptomes identify master transcription factors as functional disease drivers.
Fagnan A; Bagger FO; Piqué-Borràs MR; Ignacimouttou C; Caulier A; Lopez CK; Robert E; Uzan B; Gelsi-Boyer V; Aid Z; Thirant C; Moll U; Tauchmann S; Kurtovic-Kozaric A; Maciejewski J; Dierks C; Spinelli O; Salmoiraghi S; Pabst T; Shimoda K; Deleuze V; Lapillonne H; Sweeney C; De Mas V; Leite B; Kadri Z; Malinge S; de Botton S; Micol JB; Kile B; Carmichael CL; Iacobucci I; Mullighan CG; Carroll M; Valent P; Bernard OA; Delabesse E; Vyas P; Birnbaum D; Anguita E; Garçon L; Soler E; Schwaller J; Mercher T
Blood; 2020 Aug; 136(6):698-714. PubMed ID: 32350520
[TBL] [Abstract][Full Text] [Related]
34. Ring sideroblasts in AML are associated with adverse risk characteristics and have a distinct gene expression pattern.
Berger G; Gerritsen M; Yi G; Koorenhof-Scheele TN; Kroeze LI; Stevens-Kroef M; Yoshida K; Shiraishi Y; van den Berg E; Schepers H; Huls G; Mulder AB; Ogawa S; Martens JHA; Jansen JH; Vellenga E
Blood Adv; 2019 Oct; 3(20):3111-3122. PubMed ID: 31648334
[TBL] [Abstract][Full Text] [Related]
35. Recurrent mutations, including NPM1c, activate a BRD4-dependent core transcriptional program in acute myeloid leukemia.
Dawson MA; Gudgin EJ; Horton SJ; Giotopoulos G; Meduri E; Robson S; Cannizzaro E; Osaki H; Wiese M; Putwain S; Fong CY; Grove C; Craig J; Dittmann A; Lugo D; Jeffrey P; Drewes G; Lee K; Bullinger L; Prinjha RK; Kouzarides T; Vassiliou GS; Huntly BJ
Leukemia; 2014 Feb; 28(2):311-20. PubMed ID: 24220271
[TBL] [Abstract][Full Text] [Related]
36. Long-term survival of
Garciaz S; Berton G; Hospital MA; Guille A; Adélaïde J; Saillard C; Hicheri Y; Mozziconacci MJ; Duprez E; Récher C; Alary AS; Birnbaum D; Vey N
Leuk Lymphoma; 2024 May; 65(5):700-703. PubMed ID: 38329727
[No Abstract] [Full Text] [Related]
37. Combinatorial genetics reveals the Dock1-Rac2 axis as a potential target for the treatment of NPM1;Cohesin mutated AML.
Meyer AE; Stelloh C; Pulakanti K; Burns R; Fisher JB; Heimbruch KE; Tarima S; Furumo Q; Brennan J; Zheng Y; Viny AD; Vassiliou GS; Rao S
Leukemia; 2022 Aug; 36(8):2032-2041. PubMed ID: 35778533
[TBL] [Abstract][Full Text] [Related]
38. Combined heterozygosity of FLT3 ITD, TET2, and DNMT3A results in aggressive leukemia.
Ramdas B; Lakshmi Reddy P; Mali RS; Pasupuleti SK; Zhang J; Kelley MR; Paczesny S; Zhang C; Kapur R
JCI Insight; 2022 Sep; 7(17):. PubMed ID: 36073548
[TBL] [Abstract][Full Text] [Related]
39. TFEB links MYC signaling to epigenetic control of myeloid differentiation and acute myeloid leukemia.
Yun S; Vincelette ND; Yu X; Watson GW; Fernandez MR; Yang C; Hitosugi T; Cheng CH; Freischel AR; Zhang L; Li W; Hou H; Schaub FX; Vedder AR; Cen L; McGraw KL; Moon J; Murphy DJ; Ballabio A; Kaufmann SH; Berglund AE; Cleveland JL
Blood Cancer Discov; 2021 Mar; 2(2):162-185. PubMed ID: 33860275
[TBL] [Abstract][Full Text] [Related]
40. Mapping AML heterogeneity - multi-cohort transcriptomic analysis identifies novel clusters and divergent ex-vivo drug responses.
Severens JF; Karakaslar EO; van der Reijden BA; Sánchez-López E; van den Berg RR; Halkes CJM; van Balen P; Veelken H; Reinders MJT; Griffioen M; van den Akker EB
Leukemia; 2024 Apr; 38(4):751-761. PubMed ID: 38360865
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
